Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Paroxetine Hydrochloride vs Paxil in Healthy Chinese Volunteers
NCT03504475Phase 1Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paroxetine in major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic disorder and 2 more (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to infinity and 1 more. Started Mar 2018; status: completed.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)obsessive compulsive disorder (OCD)panic disorderSocial Anxiety Disorder (SAD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT03504475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504475.